METABOLIC SYNDROME AS A SYSTEMIC FACTOR OF THE SEVERE COURSE OF ECZEMA

Article Sidebar

PDF (Russian)
Published: 2025-12-05
DOI: https://doi.org/10.66073/researchfocus.v4i11.1876
Keywords:
eczema, metabolic syndrome, insulin resistance, microcirculation, HOMA-IR, endothelial dysfunction, triglycerides, abdominal obesity

Main Article Content

Eshonkulov Sodik Xolikovich
Samarkand Regional Branch of the Republican Specialized Scientific and Practical Medical Center of Dermatovenerology and Cosmetology. Uzbekistan, Samarkand, Panjikent street 404
Tolibov Mansur Maxmudovich
Samarkand State Medical University. Uzbekistan, Samarkand, Amir Temur street, 18

Abstract

This study assesses the influence of the components of metabolic syndrome on the severity of the course of chronic eczema in order to determine the relationship between metabolic disorders, microcirculatory changes and the clinical manifestations of the disease. The analysis was carried out by comparing patients with eczema who did and did not have metabolic syndrome. On the basis of clinical indices, biochemical indicators and laser Doppler flowmetry data, the degree of the influence of insulin resistance, dyslipidaemia and obesity on disease activity was determined. The levels of key metabolic markers, the parameters of skin microcirculation and the severity of symptoms were analysed using correlation and regression analysis. In addition, independent predictors of a severe course of eczema were identified, which is an important indicator for the development of comprehensive therapeutic and preventive strategies.

Article Details

Issue

Vol. 4 No. 11 (2025): Research Focus International Scientific Journal. Volume 4, Issue 11 (2025)

Section

14.00.00 – Medical sciences
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

METABOLIC SYNDROME AS A SYSTEMIC FACTOR OF THE SEVERE COURSE OF ECZEMA. (2025). Research Focus International Scientific Journal, 4(11), 336-343. https://doi.org/10.66073/researchfocus.v4i11.1876

References

Weidinger S., Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109–1122.

Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483–1494.

Silverberg J.I. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35(3):283–289.

Langan S.M., Irvine A.D., Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360.

Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(1):8–16.

Drucker A.M., Wang A.R., Li W.Q. The burden of atopic dermatitis. J Am Acad Dermatol. 2017;76(2):293–302.

Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome — a new worldwide definition. Lancet. 2005;366:1059–1062.

International Diabetes Federation. IDF consensus worldwide definition of the metabolic syndrome. IDF; 2022.

Grundy S.M. Metabolic syndrome update. J Clin Endocrinol Metab. 2018;103(11):3951–3958.

Egeberg A., Thyssen J.P., Gislason G. Skin disease and metabolic syndrome. J Eur Acad Dermatol Venereol. 2020;34(5):1006–1015.

Rocha-Pereira P., Santos-Silva A., Rebelo I. Inflammation in metabolic syndrome. Clin Chim Acta. 2020;506:221–230.

Lee S.Y., et al. Metabolic abnormalities and eczema severity. Allergy. 2022;77(8):2481–2492.

Hotamisligil G.S. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–867.

Ouchi N., Parker J.L., Lugus J.J., Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85–97.

Tilg H., Moschen A.R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6:772–783.

Chiesa F., Giordano R. Endothelial dysfunction in metabolic syndrome. Microvasc Res. 2020;131:104036.

Chen H., et al. Oxidative stress and endothelial damage in insulin resistance. Redox Biol. 2021;47:102198.

Egeberg A., Hansen P.R., Gislason G., Mallbris L., Skov L. Risk of eczema in patients with metabolic syndrome. JAMA Dermatol. 2017;153(8):783–789.

Lee H.J., et al. Insulin resistance and skin inflammation. Clin Exp Dermatol. 2022;47(3):534–543.

Gittler J.K., Shemer A., Suárez-Fariñas M., et al. Progressive activation of Th2/Th22 pathways in dermatitis. J Allergy Clin Immunol. 2012;130(6):1344–1354.

Tsuji G., Takahara M., Uchi H. Cytokine imbalance in chronic eczema. Int J Mol Sci. 2021;22(3):1502.

Alzolibani A. Cytokine signatures in chronic dermatitis. Clin Cosmet Investig Dermatol. 2020;13:873–880.

Choi Y.J., et al. Microvascular dysfunction in metabolic syndrome. Cardiovasc Diabetol. 2020;19:216.

Roustit M., et al. Microcirculatory alterations in skin inflammation. Microvasc Res. 2018;118:52–58.

Schaffer P., et al. Endothelial dysfunction and skin diseases. Exp Dermatol. 2021;30(8):1162–1172.

Nakamura Y., et al. Skin microbiome dysbiosis in eczema. J Allergy Clin Immunol. 2020;145(3):1021–1031.

Kong H.H., Segre J.A. Skin microbiome: emerging role in eczema pathogenesis. Nat Rev Microbiol. 2017;15(11):678–690.

Salem I., et al. Gut microbiome and skin inflammation. Exp Dermatol. 2018;27(8):815–820.

Chen B., et al. Firmicutes abundance and metabolic disorders in dermatitis. Front Immunol. 2021;12:640103.